Antisense oligonucleotides directed against human VCAM-1 RNA
US5596090A · kind A · utility
7Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 12, 1993 |
| Grant date | Jan 21, 1997 |
| Priority date | — |
| Expiry date | Oct 12, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/315
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antisense oligonucleotides complementary to human mRNAs or pre-mRNAs coding or VCAM-I are used in a therapeutic treatment of sepsis (sepsis, the sepsis syndrome, septic shock and all other manifestations of the sepsis disease, including but not inclusive of, adult respiratory distress syndrome, multi-organ failure, or cardiovascular dysfunction).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.